Your browser doesn't support javascript.
loading
Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor.
Ronayne, Estelle K; Peters, Shaun C; Gish, Joseph S; Wilson, Celena; Spencer, H Trent; Doering, Christopher B; Lollar, Pete; Spiegel, P Clint; Childers, Kenneth C.
Afiliação
  • Ronayne EK; Department of Chemistry, Western Washington University, Bellingham, WA, United States.
  • Peters SC; Department of Chemistry, Western Washington University, Bellingham, WA, United States.
  • Gish JS; Department of Chemistry, Western Washington University, Bellingham, WA, United States.
  • Wilson C; Department of Chemistry, Western Washington University, Bellingham, WA, United States.
  • Spencer HT; Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, GA, United States.
  • Doering CB; Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, GA, United States.
  • Lollar P; Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, GA, United States.
  • Spiegel PC; Department of Chemistry, Western Washington University, Bellingham, WA, United States.
  • Childers KC; Department of Chemistry, Western Washington University, Bellingham, WA, United States.
Front Immunol ; 12: 697602, 2021.
Article em En | MEDLINE | ID: mdl-34177966
ABSTRACT
Factor VIII (fVIII) is a procoagulant protein that binds to activated factor IX (fIXa) on platelet surfaces to form the intrinsic tenase complex. Due to the high immunogenicity of fVIII, generation of antibody inhibitors is a common occurrence in patients during hemophilia A treatment and spontaneously occurs in acquired hemophilia A patients. Non-classical antibody inhibitors, which block fVIII activation by thrombin and formation of the tenase complex, are the most common anti-C2 domain pathogenic inhibitors in hemophilia A murine models and have been identified in patient plasmas. In this study, we report on the X-ray crystal structure of a B domain-deleted bioengineered fVIII bound to the non-classical antibody inhibitor, G99. While binding to G99 does not disrupt the overall domain architecture of fVIII, the C2 domain undergoes an ~8 Å translocation that is concomitant with breaking multiple domain-domain interactions. Analysis of normalized B-factor values revealed several solvent-exposed loops in the C1 and C2 domains which experience a decrease in thermal motion in the presence of inhibitory antibodies. These results enhance our understanding on the structural nature of binding non-classical inhibitors and provide a structural dynamics-based rationale for cooperativity between anti-C1 and anti-C2 domain inhibitors.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator VIII / Anticorpos Monoclonais Murinos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Front Immunol Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator VIII / Anticorpos Monoclonais Murinos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Front Immunol Ano de publicação: 2021 Tipo de documento: Article